Navigation Links
Carrington Reports Second Quarter 2007 Results
Date:8/19/2007

- Revenues Down from Same Quarter Last Year - 17 Percent Quarter-to-Quarter Revenue Gain Evidences Start of Turnaround

for Core Business

- DelSite Signs Additional Agreements

IRVING, Texas, Aug. 14 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (Nasdaq: CARN) reported revenue for the quarter ended June 30, 2007 of $5.6 million, compared to $6.5 million in the year ago period. The revenue in the quarter just ended, while 17 percent higher than the $4.8 million revenue reported for the first quarter of the current year, was shy of compensating for the expected 25 percent drop in Consumer Services division revenue from the year-ago quarter due mainly to the discontinuation of certain products and expiration of a key customer's materials supply agreement, as previously reported. Also as previously reported, a new, three-year supply agreement is now in place.

Medical Services revenue for the second quarter of 2007 remained essentially unchanged from the year-ago period, at $2.2 million. Grant income received for funding of research for the Company's wholly owned drug delivery subsidiary, DelSite Biotechnologies, Inc., increased by 13 percent for the quarter, to $398,000 from $352,000 a year ago.

Net loss for the second quarter of 2007, including $801,000 of net funding of DelSite, was $2.2 million, or 20 cents per basic and diluted share, remaining basically unchanged from the net loss reported for the year-ago quarter. Pro forma loss for the quarter, exclusive of DelSite net funding, was $1.4 million compared to a $1.2 million pro forma loss in the prior year period.

"The changes we initiated to bring growth and profitabilit
'/>"/>

SOURCE Carrington Laboratories, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... A study has been launched ... the Formula 1 track could help to tackle the ... Applied Technologies (MAT), Stowhealth (a GP surgery based in ... funded by healthcare provider Simplyhealth. Telemetry technology, ... about the on-track performance of Vodafone McLaren Mercedes Formula ...
(Date:1/15/2014)... 15, 2014 The Microcompetition with Foreign ... major disease. One of these latent viruses is the ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a ... predicted by the theory, a study found that RA ... bodies (1). , What is Microcompetition? , Dr. ...
(Date:1/15/2014)... January 15, 2014 Freeslate, ... research solutions, today announced that Lupin Limited, one ... delivery of Freeslate’s CM Protégé PharmD System ... , Lupin, headquartered in Mumbai, India, is focused ... and branded formulations and Active Pharmaceutical Ingredients (APIs) ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 ... Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... national nonprofit organization solely dedicated to finding a cure ... for those affected worldwide, will host its annual Crystal ... in Warrington, Pa. , Each year, the Crystal ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... MEDX ) announced today that it has completed the ... stock is traded on the,Copenhagen Stock Exchange. The trade ... to receive approximately $151.8 million (USD) in net,proceeds from ... in Genmab to approximately 5.1 percent., About Medarex, ...
... Use of vitamin and mineral supplements,among cancer survivors ... beneficial, according to a comprehensive review of scientific,literature ... and published Feb. 1 in the Journal of ... reduce the adverse effects of,cancer treatment, decrease the ...
... 31 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:,WX) today ... AppTec Laboratory,Services, Inc., a US-based service provider ... offers testing, contract research and,development, and cGMP ... integrated platform., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ...
Cached Biology Technology:Study Finds Widespread Vitamin and Mineral Use Among Cancer Survivors, Although Benefits of Such Use Remain Unclear 2Study Finds Widespread Vitamin and Mineral Use Among Cancer Survivors, Although Benefits of Such Use Remain Unclear 3WuXi PharmaTech Completes Acquisition of AppTec 2
(Date:4/15/2014)... The American Association of Anatomists (AAA) is honored to ... be presented during the Closing Awards Ceremony being held ... 29th at 7:30 p.m. during AAA,s 2014 Annual Meeting ... award winners are: , Henry Gray/Elsevier Distinguished ... School of Medicine at Mount Sinai, Past-President of the ...
(Date:4/15/2014)... diseases in the world for which no pharmaceutical treatment ... spread by mosquitoes in the tropics, as well as ... Finland and is easily spread by the hands and ... elderly. , Researchers at Aalto University and the University ... to prevent the spread of one type of virus ...
(Date:4/15/2014)... Adelaide research into parasites of cuttlefish, squid and ... life cycles, and shown how they may help ... Dr Sarah Catalano has described 10 new parasite ... kidneys of cephalopods (cuttlefish, squid and octopus). ... be described from Australian waters. , "Although ...
Breaking Biology News(10 mins):American Association of Anatomists 2014 award winners 2Nanocrystalline cellulose modified into an efficient viral inhibitor 2Bizarre parasite may provide cuttlefish clues 2
... to control invasive winter moths with a natural parasite ... Massachusetts Amherst now has concrete evidence that a parasitic ... the pest at four sites in Seekonk, Hingham, Falmouth ... the decade-long defoliation of eastern Massachusetts trees by the ...
... Muslimov, MD, PhD, along with senior author Henri Tiedge, ... published a study suggesting that cellular dysregulation associated with ... neuronal RNA transport pathways. The paper appeared ... "Spatial Code Recognition in Neuronal RNA Targeting: Role of ...
... proteins whose activity and lifetime must be regulated to control the ... shock protein Hsp90 plays a key role in this process. It ... monitors and controls the quality and activity of many important signal ... cell is exposed to high stress levels from heat or a ...
Cached Biology News:UMass Amherst entomologists begin to control winter moth infestation in eastern Massachusetts 2Researchers publish study on neuronal RNA targeting 2A chaperone for the 'guardian of the genome' 2A chaperone for the 'guardian of the genome' 3
Mouse NOV/CCN3 Affinity Purified Polyclonal Ab...
Human Complement Component C5a MAb (Clone 295003)...
Human Serpin A8/AGT Affinity Purified Polyclonal Ab Keywords: Ang II, AngII, Hypertension, Salt Homeostasis, Pre-eclampsia...
Mouse Axl MAb (Clone 175128)...
Biology Products: